Karen Swanson, DO
Pulmonary Disease · Scottsdale, AZNPI 1316911605
Payments from drug & device makers
What this record shows
9 manufacturers reported payments, led by Intuitive Surgical at 44.6% of the total. Reporting peaked in 2023 at $1,626 and has fallen 85.1% since, to $243 in 2025.
Across 37 payments — averaging $97.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Johnson & Johnson$723
- Pulmonx Corporation$416
- Actelion Pharmaceuticals US, Inc.$236
- Covidien LP$208
- Galvanize Therapeutics, Inc$130
- plus $281 from 3 others
Across 18 payments — averaging $9429.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$170K
What the payments were for
- Travel & lodging$1,83451%
- Food & beverage$1,76649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $1,606 |
| Johnson & Johnson | 6 | $723 |
| Pulmonx Corporation | 2 | $416 |
| Actelion Pharmaceuticals US, Inc. | 4 | $236 |
| Covidien LP | 6 | $208 |
| Galvanize Therapeutics, Inc | 1 | $130 |
| Medtronic | 1 | $130 |
| United Therapeutics Corporation | 1 | $125 |
| Olympus Corporation Of The Americas | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$984
- MONARCH$694
- Pulmonx Endobronchial Valve EBV$347
- ALIYA SYSTEM$130
- Signia$130
- TYVASO$125
How this compares
$3,601 in reported general payments places this provider in the 55th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 48 | $630,453 |
| OpsumitMacitentan | 36 | $441,964 |
| AdempasRiociguat | 22 | $299,472 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $29,189 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $17,815 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $9,138 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,833 |
| Tadalafil | 11 | $4,324 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,192 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $489 |
| Furosemide | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $236 | $441,96436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Scottsdale
- Suchitra PilliScottsdale$38K
- Laszlo VaszarScottsdale$18K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Richard SueGilbert$224K
- Mark GotfriedPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.